Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients

Expert Review of Anticancer Therapy

Volumn 10, Issue 6, 2010, Pages 825-835

  Bellmunt, Joaquim ^a   Fishman, Mayer ^b   Eisen, Timothy ^c   Quinn, David ^d  

^a HOSPITAL DEL MAR   (Spain)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Elderly; Multiple lines of therapy; Patient adherence; Quality of life; Renal cell carcinoma; Sorafenib; Systemic therapy; Watch and wait

Indexed keywords

ALPHA INTERFERON; AXITINIB; CEDIRANIB; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG CHOICE; ELDERLY CARE; FATIGUE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; METASTASIS; NEPHRECTOMY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY OF LIFE; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; PATHOLOGY; SECONDARY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIDINES;

EID: 77953782584     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.68     Document Type: Review

References (76)

1. Vakkalanka B, Rini BI. Targeted therapy in renal cell carcinoma. Curr. Opin. Urol. 18(5), 481-487 (2008).
2. Lacouture M, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction. Oncologist 13(9), 1001-1011 (2008).
3. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10), 3129-3140 (2008).
4. Nexavar® , package insert. Bayer HealthCare Pharmaceuticals, NJ, USA (2008).
5. Wilhelm S, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004).
6. deReijke T, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur. J. Cancer 45(5), 765-773 (2009).
7. Levi, Ferlay J, Galeone C et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 101(8), 949-958 (2008).
8. Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol. DOI: 10.1155/2008/782381 (2008) (Epub ahead of print).
9. Bellmunt J, Calvo E, Castellano D et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother. Pharmacol. 63(S1), S1-S13 (2009).
10. Pathology and genetics of tumours of the urinary system and male genital organs. In: WHO Classification of Tumours (Volume 7). Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Eds). IARC Press, Lyon, France (2004).
11. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur. Urol. 49(5), 798-805 (2006).
12. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34, 193-205 (2008).
13. Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(25), 4076-4081 (2009).
14. Beisland C, Hjelle KM, Reisaeter LA, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur. Urol. 55(6), 1419-1427 (2009).
15. Wong A, Chong KT, Heng CT et al. Debulking nephrectomy followed by a "watch and wait" approach in metastatic renal cell carcinoma. Urol. Oncol. 27(2), 149-154 (2009).
16. Rini B, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 373(9669), 1119-1132 (2009).
17. Kroog G, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol. Clin. N. Am. 35(4), 687-701 (2008).
18. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (3), CD001425 (2004).
19. Avastin® , package insert. Genentech, Inc., CA, USA (2009).
20. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
21. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(16), 2505-2512 (2006). (Pubitemid 46630627)
22. Grandinetti C, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell carcinoma. Pharmacotherapy 27(8), 1125-1144 (2007).
23. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27(20), 3312-3318 (2009).
24. Beck J, Bajetta E, Escudier B et al. A large open label, non comparative Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Presented at: ECCO. Barcelona, Spain, 23-27 September 2007.
25. Stadler W, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5), 1272-1280 (2010).
26. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
27. Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon a-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(8), 1280-1289 (2009).
28. Dudek A, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115(1), 61-67 (2009).
29. Vickers M, Choueiri TK, Zama I et al. Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): what next? J. Clin. Oncol. 27(15S), 5098 (2009).
30. Sablin M, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 182(1), 29-34 (2009).
31. Gelderblom H, Montemurro M, Schutte J et al. Sorafenib fourth-line treatment in imatinib, sunitinib, and nilotinib resistant metastatic GIST: a retrospective analysis. Presented at: ASCO. FL, USA, 29 May-2 June 2009.
32. Daher I, Yeh ET. Vascular complications of selected cancer therapies. Nat. Clin. Pract. Cardiovasc. Med. 5(12), 797-805 (2008).
33. Lenihan D. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J. Clin. Oncol. 26(32), 5154-5155 (2008).
34. Zucchetto A, Dal Maso L, Tavani A et al. History of treated hypertension and diabetes mellitus and risk of renal cell carcinoma. Ann. Oncol. 18(3), 596-600 (2007).
35. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343(18), 1305-1311 (2000).
36. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7(5), 332-344 (2007). (Pubitemid 46652481)
37. Bhargava P, Esteves B, Nosov DA et al. Updated activity and safety results of a Phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J. Clin. Oncol. 27(15S), 5032 (2009).
38. Robinson ES, Matulonis UA, Ivy P et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin. J. Am. Soc. Nephrol. 5(3), 477-483 (2010).
39. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Rev. DOI: 10.1016/j. ctrv.2010.01.003 (2010) (Epub ahead of print).
40. Snow H, Brueckner A, Gelder M. Sorafenib is not associated with a high incidence of cardiovascular events in many tumor types. Presented at: ESMO. Stockholm, Sweden, 12-16 September 2008.
41. Veronese M, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24(9), 1363-1369 (2006).
42. Harshman L, Telli ML, Witteles RM, Srinivas S. Low incidence of symptomatic cardiotoxicity associated with sorafenib in patients with metastatic renal cell carcinoma: an institutional experience. Presented at: ASCO-GU. FL, USA, 22-24 January 2009.
43. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26(32), 5204-5212 (2008).
44. Eisen T, Beck J, Procopio G et al. Large open-label, non-comparative Phase III study of sorafenib in European patients with advanced renal cell carcinoma (EUARCCS) - subgroup analysis of patients with and without baseline clinical cardiovascular diseases (CCD). Presented at: ESMO. Stockholm, Sweden, 12-16 September 2008.
45. Lucas SM, Nuss G, Stern J et al. The Screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses. Cancer 113(10), 2681-2686 (2008).
46. Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin. Genitourin. Cancer. 7(2), E10-E15 (2009).
47. Hilger RA, Richly H, Grubert M et al. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int. J. Clin. Pharmacol. Ther. 47(1), 61-64 (2009).
48. Miller AA, Murray DJ, Owzar K et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 27(11), 1800-1805 (2009).
49. Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. The medical treatment of metastatic renal cancer in the elderly: position paper of a SIOG taskforce. Crit. Rev. Oncol. Hematol. 69(1), 64-72 (2009).
50. Extermann M. Interaction between comorbidity and cancer. Cancer Control 14(1), 13-22 (2007).
51. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J. Clin. Oncol. 25(14), 1824-1831 (2007). (Pubitemid 46860271)
52. Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst. 100(20), 1454-1463 (2008).
53. Porta C, Bracarda S, Beck J et al. Efficacy and safety of sorafenib in elderly patients: results from a large open label non-comparative Phase III study in European patients with advanced RCC (EU ARCCS). Ann. Oncol. 19(S8), 596P (2008).
54. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10(8), 757-763 (2009).
55. Lonardi S, Bortolami A, Stefani M, Monfardini S. Oral anticancer drugs in the elderly. Drugs Aging 24(5), 395-410 (2007).
56. Fallowfield L. There's many a slip twixt cup and lip: adherence issues in cancer therapy. Nat. Clin. Pact. Oncol. 5(3), 118-119 (2008).
57. Winkeljohn DL. Oral chemotherapy medications: the need for a nurse's touch. Clin. J. Oncol. Nurs. 11(6), 793-796 (2007).
58. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J. Clin. 59(1), 56-66 (2009).
59. Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME. Search for evidence based approaches for the prevention and palliation of hand foot skin reaction caused by the multikinase inhibitors. Oncologist 14(3), 291-302 (2009).
60. Alexandrescu D, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin. Exp. Dermatol. 32(1), 71-74 (2007).
61. Wood L, Manchen B. Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clin. J. Oncol. Nurs. 11(5), 649-656 (2007).
62. Bukowski R, Cella D, Gondek K, Escudier B; Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo controlled study in renal cell cancer. Am. J. Clin. Oncol. 30(3), 220-227 (2007).
63. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12(12), 1005-1016 (2005).
64. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30(8), 825-830 (2007).
65. Hudes G, Carducci M, Tomczak P et al.; Global ARCC Trial. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007). (Pubitemid 46849157)
66. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-a on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 26(2), 202-209 (2009).
67. Motzer RJ, Escudier B, Oudard S et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
68. Figlin RA, de Souza P, McDermott D et al. Analysis of PTEN and HIF-1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-a. Cancer 115(16), 3651-3660 (2009).
69. European Medicines Agency. Committee for orphan medical products: public summary of positive opinion for orphan designation of sorafenib tosylate for the treatment of renal cell carcinoma www.emea.europa.eu/pdfs/human/comp/ opinion/029404en.pdf (Accessed 10 February 2009)
70. NCCN. NCCN practice guidelines in oncology: kidney cancer www.nccn.org/professionals/physician- gls/f-guidelines.asp (Accessed 3 March 2009)
71. Clinicaltrials.gov. Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer www.clinicaltrials.gov/ct2/ show/ NCT00492258?term=SORCE&rank=2 (Accessed 7 April 2010)
72. Clinicaltrials.gov. Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery www.clinicaltrials.gov/ct2/show/ NCT00326898?term=ASSURE&rank=4 (Accessed 7 April 2010)
73. Clinicaltrials.gov. A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC) www.clinicaltrials.gov/ct2/show/ NCT00375674?term=S-TRAC&rank=1 (Accessed 7 April 2010)
74. Clinicaltrials.gov. Sequential study to treat renal cell carcinoma www.clinicaltrials.gov/ct2/show/NCT007 32914?term=sorafenib+sunitinib&rank=2 (Accessed 6 August 2009)
75. Clinicaltrials.gov. Sunitinib malate schedule 4/2 vs sunitinib malate continuous dosing as first-line therapy for metastatic renal cell cancer http://clinicaltrials.gov/ct2/show/ NCT00267748
76. Clinicaltrials.gov. Sunitinib of sorafenib in treating patients with kidney cancer that was removed by surgery www.clinicaltrials.gov/ct2/show/ NCT00326898?term-ASSURE&rank-2 (Accessed 6 August 2009)